Century Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Century Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Century Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Century Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Century Therapeutics Inc (Century Therapeutics) is a biotechnology company. It develops cell therapies for the treatment of cancer. The company pipeline products include CNTY-101 for the treatment of B-cell-mediated autoimmune diseases; CNTY-308 which treats B-cell-mediated autoimmune diseases and B-cell malignancies; CNTY-341 treats B-cell malignancies and solid tumors. It involves pluripotent stem cells (iPSCs), gene editing, protein engineering and manufacturing to develop next generation cell therapies that can be dosed as needed until every patient achieves a durable response. Century Therapeutics is headquartered in Philadelphia, Pennsylvania, the US.
Headquarters
United States of America
Address
25 N 38th Street, 11th Floor, Philadelphia, Pennsylvania, 19104
Website
www.centurytx.com
No of Employees
78
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
IPSC (NASD)
Revenue (2025)
$109.2M
1556.8%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
92.4%
(2025 vs 2024)
Market Cap*
$349.5M
Net Profit Margin (2025)
XYZ
99.5%
(2025 vs 2024)
* As of and is in US$
Century Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| CNTY-101: B-Cell-Mediated Autoimmune Diseases |
| CNTY-308: B-Cell-Mediated Autoimmune Diseases and B-Cell Malignancies |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Century Therapeutics Inc | AstraZeneca Plc | Bristol-Myers Squibb Co | Gilead Sciences Inc | Editas Medicine Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United Kingdom | United States of America | United States of America | United States of America |
| City | Philadelphia | Cambridge | Princeton | Foster City | Cambridge |
| State/Province | Pennsylvania | Cambridgeshire | New Jersey | California | Massachusetts |
| No. of Employees | 78 | 96,100 | 32,500 | 17,000 | 87 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Joseph Jimenez | Chairman | Executive Board | 2019 | 65 |
| Brent Pfeiffenberger | Chief Executive Officer; Director; President | Executive Board | 2024 | 47 |
| Morgan Conn, Ph.D. | Chief Financial Officer | Senior Management | 2024 | 56 |
| Gregory Russotti, Ph.D. | Chief Manufacturing Officer; Chief Technology Officer | Senior Management | 2023 | 58 |
| Chad Cowan, Ph.D. | Chief Scientific Officer | Senior Management | 2024 | 63 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer